Legacy Capital Wealth Partners LLC cut its position in shares of GSK plc (NYSE:GSK - Free Report) by 59.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,088 shares of the pharmaceutical company's stock after selling 23,681 shares during the quarter. Legacy Capital Wealth Partners LLC's holdings in GSK were worth $544,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Indiana Trust & Investment Management Co boosted its holdings in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Eastern Bank bought a new stake in GSK in the third quarter worth $26,000. Crews Bank & Trust bought a new stake in GSK in the fourth quarter worth $26,000. ST Germain D J Co. Inc. boosted its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 522 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after acquiring an additional 302 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.
GSK stock opened at $36.20 on Monday. The stock has a market cap of $75.02 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. GSK plc has a one year low of $31.72 and a one year high of $45.92. The stock has a fifty day moving average of $34.42 and a 200 day moving average of $37.45.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts predict that GSK plc will post 4.07 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.34%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is 93.08%.
GSK has been the topic of several analyst reports. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and lowered their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.
Read Our Latest Stock Analysis on GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.